JPWO2020128049A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020128049A5 JPWO2020128049A5 JP2021535950A JP2021535950A JPWO2020128049A5 JP WO2020128049 A5 JPWO2020128049 A5 JP WO2020128049A5 JP 2021535950 A JP2021535950 A JP 2021535950A JP 2021535950 A JP2021535950 A JP 2021535950A JP WO2020128049 A5 JPWO2020128049 A5 JP WO2020128049A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- heavy chain
- bispecific antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 239000003814 drug Substances 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 8
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 5
- 208000009292 Hemophilia A Diseases 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 229950006925 emicizumab Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 238000005734 heterodimerization reaction Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1820977.5 | 2018-12-21 | ||
| GBGB1820977.5A GB201820977D0 (en) | 2018-12-21 | 2018-12-21 | Fixaxfx bispecific antibody with commomn light chain |
| GB1906816.2 | 2019-05-15 | ||
| GBGB1906816.2A GB201906816D0 (en) | 2019-05-15 | 2019-05-15 | FIXaxFX bispecific antibody with common light chain |
| GB1908190.0 | 2019-06-07 | ||
| GBGB1908190.0A GB201908190D0 (en) | 2019-06-07 | 2019-06-07 | Fixaxfx bispecific antibody with common light chain |
| PCT/EP2019/086808 WO2020128049A1 (en) | 2018-12-21 | 2019-12-20 | Fixaxfx bispecific antibody with common light chain |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022515770A JP2022515770A (ja) | 2022-02-22 |
| JP2022515770A5 JP2022515770A5 (https=) | 2022-12-28 |
| JPWO2020128049A5 true JPWO2020128049A5 (https=) | 2022-12-28 |
| JP7530362B2 JP7530362B2 (ja) | 2024-08-07 |
Family
ID=69167786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535950A Active JP7530362B2 (ja) | 2018-12-21 | 2019-12-20 | 共通の軽鎖を有するＦＩＸａ×ＦＸ二重特異性抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10815308B2 (https=) |
| EP (2) | EP3723858B1 (https=) |
| JP (1) | JP7530362B2 (https=) |
| KR (1) | KR20210118085A (https=) |
| CN (1) | CN113453757B (https=) |
| BR (1) | BR112021012065A2 (https=) |
| CA (1) | CA3123177A1 (https=) |
| DK (1) | DK3723858T3 (https=) |
| ES (1) | ES2901683T3 (https=) |
| HR (1) | HRP20220088T1 (https=) |
| HU (1) | HUE057634T2 (https=) |
| LT (1) | LT3723858T (https=) |
| PL (1) | PL3723858T3 (https=) |
| PT (1) | PT3723858T (https=) |
| RS (1) | RS62848B1 (https=) |
| SI (1) | SI3723858T1 (https=) |
| TW (1) | TWI772724B (https=) |
| WO (1) | WO2020128049A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| PL3723858T3 (pl) * | 2018-12-21 | 2022-03-07 | Kymab Limited | Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim |
| GB2590642B (en) * | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
| US20230250192A1 (en) * | 2019-05-15 | 2023-08-10 | Kymab Limited | Improved lambda antibodies |
| CN115728433B (zh) * | 2021-08-27 | 2024-11-15 | 联邦生物科技(珠海横琴)有限公司 | IgG4型单克隆抗体电荷异质性的离子交换色谱检测方法 |
| WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
| WO2023147574A2 (en) * | 2022-01-31 | 2023-08-03 | The Children's Hospital Of Philadelphia | Compositions and methods for treating factor ix deficiency |
| AR129879A1 (es) * | 2022-07-08 | 2024-10-09 | Novo Nordisk As | Compuestos de isvd altamente potentes capaces de sustituir al fviii(a) |
| GB202319967D0 (en) | 2023-12-22 | 2024-02-07 | Epsilogen Ltd | Heteromultimeric proteins |
| WO2026036047A1 (en) * | 2024-08-08 | 2026-02-12 | Altus Enterprises, Inc. | Antibody molecules to fixa and fx and uses thereof |
| WO2026037918A1 (en) | 2024-08-14 | 2026-02-19 | Epsilogen Ltd | Heteromultimeric proteins |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| WO2005035754A1 (ja) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| CA2603264C (en) | 2005-04-08 | 2017-03-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
| KR20080030960A (ko) | 2005-07-05 | 2008-04-07 | 글락소 그룹 리미티드 | Ｎｏｇｏ―ａ에 특이적인 인간화된 항체 및 이의 약제학적용도 |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| US20080102065A1 (en) * | 2006-04-14 | 2008-05-01 | Borges Luis G | Erythropoietin receptor extended duration limited agonists |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| KR101856792B1 (ko) * | 2009-12-25 | 2018-05-11 | 추가이 세이야쿠 가부시키가이샤 | 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법 |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| PH12016502073B1 (en) * | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| US20140356377A1 (en) | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| EP2906599B1 (en) | 2012-10-12 | 2019-07-17 | Agency For Science, Technology And Research | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| RU2687043C2 (ru) * | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN105848668A (zh) | 2013-11-04 | 2016-08-10 | 加利福尼亚大学董事会 | 治疗或预防与出血或低凝血相关联的病状的疗法 |
| BR112016015140A2 (pt) | 2013-12-30 | 2018-01-23 | Epimab Biotherapeutics Inc. | imunoglobulina com fabs in-tandem e usos das mesmas |
| TWI831106B (zh) | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| CA2978038A1 (en) | 2015-04-17 | 2016-10-20 | F. Hoffmann-La Roche Ag | Combination therapy with coagulation factors and multispecific antibodies |
| JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物 |
| EP3313871A1 (en) * | 2015-06-26 | 2018-05-02 | Institute for Research in Biomedicine | Proteins comprising a mutated lair-1 fragment and uses thereof |
| JP6920293B2 (ja) | 2015-10-30 | 2021-08-18 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ＩｇＧ軽鎖におけるＮ末端切断の防止 |
| US20200270363A1 (en) | 2015-12-25 | 2020-08-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| WO2017132827A1 (en) * | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| RU2767329C2 (ru) | 2016-02-06 | 2022-03-17 | Эпимаб Биотерапьютикс, Инк. | Иммуноглобулин с тандемными fab-фрагментами и варианты его применения |
| CN109563154B (zh) | 2016-05-16 | 2024-12-13 | 武田药品工业株式会社 | 抗帕多瓦因子ix抗体 |
| KR102591955B1 (ko) * | 2016-07-29 | 2023-10-19 | 추가이 세이야쿠 가부시키가이샤 | 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체 |
| RU2766233C2 (ru) | 2016-09-06 | 2022-02-10 | Чугаи Сейяку Кабусики Кайся | Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x |
| US20230192896A1 (en) * | 2016-11-23 | 2023-06-22 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
| EP3577140A1 (en) | 2017-02-01 | 2019-12-11 | Novo Nordisk A/S | Procoagulant antibodies |
| US20210284715A1 (en) | 2017-02-06 | 2021-09-16 | Applied Stemcell, Inc. | Coagulation factor viii mimetic protein and uses thereof |
| IL270138B2 (en) * | 2017-04-26 | 2025-08-01 | Eureka Therapeutics Inc | Structures that specifically recognize glypican 3 and their uses |
| EP3621643A4 (en) | 2017-05-11 | 2021-07-21 | Atreca, Inc. | ANTIBODY ANTI-MALARIA BOUND WITH CIRCUMSPOROZOID PROTEIN |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| AR113142A1 (es) | 2017-09-29 | 2020-01-29 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo |
| US11787874B2 (en) | 2017-11-15 | 2023-10-17 | Novo Nordisk A/S | Factor X binders enhancing FX activation |
| PL3723858T3 (pl) * | 2018-12-21 | 2022-03-07 | Kymab Limited | Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim |
-
2019
- 2019-12-20 PL PL19836806T patent/PL3723858T3/pl unknown
- 2019-12-20 PT PT198368060T patent/PT3723858T/pt unknown
- 2019-12-20 US US16/722,452 patent/US10815308B2/en active Active
- 2019-12-20 HU HUE19836806A patent/HUE057634T2/hu unknown
- 2019-12-20 EP EP19836806.0A patent/EP3723858B1/en active Active
- 2019-12-20 WO PCT/EP2019/086808 patent/WO2020128049A1/en not_active Ceased
- 2019-12-20 HR HRP20220088TT patent/HRP20220088T1/hr unknown
- 2019-12-20 US US17/311,595 patent/US20220064327A1/en not_active Abandoned
- 2019-12-20 LT LTEPPCT/EP2019/086808T patent/LT3723858T/lt unknown
- 2019-12-20 SI SI201930150T patent/SI3723858T1/sl unknown
- 2019-12-20 BR BR112021012065A patent/BR112021012065A2/pt not_active Application Discontinuation
- 2019-12-20 ES ES19836806T patent/ES2901683T3/es active Active
- 2019-12-20 DK DK19836806.0T patent/DK3723858T3/da active
- 2019-12-20 KR KR1020217022770A patent/KR20210118085A/ko not_active Ceased
- 2019-12-20 CA CA3123177A patent/CA3123177A1/en active Pending
- 2019-12-20 TW TW108146911A patent/TWI772724B/zh active
- 2019-12-20 CN CN201980091786.3A patent/CN113453757B/zh active Active
- 2019-12-20 EP EP21204339.2A patent/EP4015538A1/en active Pending
- 2019-12-20 RS RS20220069A patent/RS62848B1/sr unknown
- 2019-12-20 JP JP2021535950A patent/JP7530362B2/ja active Active
-
2020
- 2020-10-06 US US17/063,905 patent/US11976135B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025134874A (ja) | ブラジキニンｂ１受容体リガンドに対する抗体 | |
| US11591406B2 (en) | Treatment for multiple myeloma (MM) | |
| CN119679936A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| EA034767B1 (ru) | Человеческие антитела к белку f респираторного синцитиального вируса и способы их применения | |
| JP2017536354A5 (https=) | ||
| CN106794244A (zh) | 用于降低心血管风险的方法 | |
| AU2021339954A1 (en) | Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma | |
| JP2017534646A5 (https=) | ||
| CN104684552A (zh) | 组合及其用途 | |
| JP2020513757A5 (https=) | ||
| JP2017534645A5 (https=) | ||
| JPWO2020128049A5 (https=) | ||
| CN111787981A (zh) | 改变身体组成的方法 | |
| WO2017059813A1 (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| CN1311691A (zh) | 抗凝剂和人源化抗冯·维勒布兰德氏因子的单克隆抗体 | |
| WO2015028888A2 (en) | Pharmaceutical compositions to treat viral infection | |
| US20250296988A1 (en) | Combination therapy | |
| US20230406942A1 (en) | Igf1r antibodies | |
| JPWO2022256559A5 (https=) | ||
| JPWO2023019171A5 (https=) | ||
| WO2023051669A1 (zh) | 喹啉衍生物与抗cd47抗体的药物组合 | |
| TW202114734A (zh) | Il-17拮抗劑治療自身免疫疾病的方法 | |
| JPWO2022187510A5 (https=) | ||
| RU2025129547A (ru) | Способы применения мультиспецифических связывающих белков | |
| WO2025130748A1 (zh) | 一种抗凝血因子XI/XIa抗体制剂 |